Samantha I Pitts1, Noah Barasch2, Andrew T Maslen3, Bridgette A Thomas4, Leonard P Dorissaint3, Krista G Decker5, Sadaf Kazi2, Yushi Yang6, Allen R Chen7. 1. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States. 2. Armstrong Institute for Patient Safety and Quality, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States. 3. Information Technology, Johns Hopkins Health System, Baltimore, Maryland, United States. 4. Pharmacy Services, Johns Hopkins Home Care Group, Baltimore, Maryland, United States. 5. Department of Quality Management, Johns Hopkins Home Care Group, Baltimore, Maryland, United States. 6. Armstrong Institute for Patient Safety and Quality, Johns Hopkins Health System, Baltimore, Maryland, United States. 7. Departments of Oncology and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.
Abstract
BACKGROUND: CancelRx allows prescribers to send electronic cancellation messages to pharmacies when medications are discontinued. Little is known about its functionality and impact on clinical workflows. OBJECTIVES: To understand CancelRx functionality, its potential impact on workflows and medication safety risks, and to develop mitigating strategies for risks introduced by implementation. METHODS: We conducted direct observations and semi-structured interviews to develop CancelRx use cases and assessed CancelRx in an end-to-end test environment, proactive risk assessment, and pilot implementation from April 16 to July 15, 2018. RESULTS: E-cancellations were sent upon discontinuation of e-prescriptions written within the electronic health record (EHR), but not other medications (e.g., printed prescriptions) and could be initiated by nonprescribers. In our proactive risk assessment, CancelRx implementation eliminated five of seven failure modes in outpatient prescribing to Johns Hopkins pharmacies, but introduced new risks, including (1) failure to act if an e-cancellation was not sent or was unsuccessful; (2) failure to cancel all prescriptions for a medication; (3) errors in manual matching; and (4) erroneous medication cancellations. We identified potential mitigation strategies for these risks. During pilot implementation, 92.4% (428/463) of e-cancellations had confirmed approval by the receiving pharmacy, while 4.5% (21/463) were denied, and 3.0% (14/463) had no e-cancellation response. Among e-cancellations received by the pilot pharmacy, 1.7% (7/408) required manual matching by pharmacy staff. Based on performance in testing, 73.4% (340/463) of completed e-cancellations would be expected to generate an in-basket message, including 21 (6.2%) denials and 319/340 (93.8%) approvals with a note from the pharmacy. CONCLUSION: CancelRx is an important functionality with the potential to decrease adverse events due to medication errors. However, changes in implementation in our EHR and pharmacy software and enhancements in the CancelRx standard are needed to maximize safety and usability. Further studies are needed to evaluate the impact of e-cancellation on medication safety. Georg Thieme Verlag KG Stuttgart · New York.
BACKGROUND: CancelRx allows prescribers to send electronic cancellation messages to pharmacies when medications are discontinued. Little is known about its functionality and impact on clinical workflows. OBJECTIVES: To understand CancelRx functionality, its potential impact on workflows and medication safety risks, and to develop mitigating strategies for risks introduced by implementation. METHODS: We conducted direct observations and semi-structured interviews to develop CancelRx use cases and assessed CancelRx in an end-to-end test environment, proactive risk assessment, and pilot implementation from April 16 to July 15, 2018. RESULTS: E-cancellations were sent upon discontinuation of e-prescriptions written within the electronic health record (EHR), but not other medications (e.g., printed prescriptions) and could be initiated by nonprescribers. In our proactive risk assessment, CancelRx implementation eliminated five of seven failure modes in outpatient prescribing to Johns Hopkins pharmacies, but introduced new risks, including (1) failure to act if an e-cancellation was not sent or was unsuccessful; (2) failure to cancel all prescriptions for a medication; (3) errors in manual matching; and (4) erroneous medication cancellations. We identified potential mitigation strategies for these risks. During pilot implementation, 92.4% (428/463) of e-cancellations had confirmed approval by the receiving pharmacy, while 4.5% (21/463) were denied, and 3.0% (14/463) had no e-cancellation response. Among e-cancellations received by the pilot pharmacy, 1.7% (7/408) required manual matching by pharmacy staff. Based on performance in testing, 73.4% (340/463) of completed e-cancellations would be expected to generate an in-basket message, including 21 (6.2%) denials and 319/340 (93.8%) approvals with a note from the pharmacy. CONCLUSION: CancelRx is an important functionality with the potential to decrease adverse events due to medication errors. However, changes in implementation in our EHR and pharmacy software and enhancements in the CancelRx standard are needed to maximize safety and usability. Further studies are needed to evaluate the impact of e-cancellation on medication safety. Georg Thieme Verlag KG Stuttgart · New York.
Authors: Tejal K Gandhi; Saul N Weingart; Joshua Borus; Andrew C Seger; Josh Peterson; Elisabeth Burdick; Diane L Seger; Kirstin Shu; Frank Federico; Lucian L Leape; David W Bates Journal: N Engl J Med Date: 2003-04-17 Impact factor: 91.245
Authors: Ross Koppel; Joshua P Metlay; Abigail Cohen; Brian Abaluck; A Russell Localio; Stephen E Kimmel; Brian L Strom Journal: JAMA Date: 2005-03-09 Impact factor: 56.272
Authors: James M Walker; Pascale Carayon; Nancy Leveson; Ronald A Paulus; John Tooker; Homer Chin; Albert Bothe; Walter F Stewart Journal: J Am Med Inform Assoc Date: 2008-02-28 Impact factor: 4.497
Authors: Clare L Brown; Helen L Mulcaster; Katherine L Triffitt; Dean F Sittig; Joan S Ash; Katie Reygate; Andrew K Husband; David W Bates; Sarah P Slight Journal: J Am Med Inform Assoc Date: 2017-03-01 Impact factor: 4.497
Authors: Taylor L Watterson; Jamie A Stone; Roger Brown; Ka Z Xiong; Anthony Schiefelbein; Edmond Ramly; Peter Kleinschmidt; Michael Semanik; Lauren Craddock; Samantha Pitts; Taylor Woodroof; Michelle A Chui Journal: J Am Med Inform Assoc Date: 2021-07-14 Impact factor: 4.497
Authors: Taylor L Watterson; Jamie A Stone; Aaron Gilson; Roger Brown; Ka Z Xiong; Anthony Schiefelbein; Edmond Ramly; Peter Kleinschmidt; Michael Semanik; Lauren Craddock; Samantha I Pitts; Taylor Woodroof; Michelle A Chui Journal: BMC Med Inform Decis Mak Date: 2022-02-25 Impact factor: 2.796
Authors: Taylor L Watterson; Sara E Hernandez; Jamie A Stone; Aaron M Gilson; Edmond Ramly; Michelle A Chui Journal: Explor Res Clin Soc Pharm Date: 2022-01-25